文献速递免疫规划传染病防控与疫情报告

韩国儿童皮内丹麦株与经皮东京株卡介苗接种的安全性:全国性队列研究

Safety of intradermal Danish- vs. transcutaneous Tokyo-strain BCG vaccination in Korean children: A nationwide cohort study.
PubMed 文献 · Vaccine · 2025-10-03

该全国性回顾性队列纳入2014—2018年出生并接种卡介苗的儿童,比较皮内丹麦1331株与经皮东京172株的安全性。淋巴腺炎在皮内组发生率9.27%、经皮组8.87%(P<0.001),但校正后风险比1.00(95%CI 0.99-1.02);骨炎两组均罕见。作者认为两种方法安全性良好,政策选择可基于供应与后勤。

要点

  • 皮内丹麦株与经皮东京株卡介苗的淋巴腺炎发生率分别为9.27%与8.87%,校正后风险无差异(aHR 1.00,95%CI 0.99-1.02)。
  • 骨炎在两组均罕见(142例 vs 209例,各约0.03%;aHR 1.01,95%CI 0.80-1.26)。
  • 作者认为两种接种方法安全有效,选择可依据疫苗供应、接种后勤和地方偏好。

核心结论

  • 皮内丹麦1331株与经皮东京172株卡介苗对儿童结核病的保护效果相当,皮内接种仅与淋巴腺炎非常小幅增加相关,严重不良事件在两种方法中均不常见。

研究设计与样本

  • 全国性回顾性队列,纳入2014—2018年出生并在婴儿期接种卡介苗的儿童(N=1,217,695;皮内丹麦株n=457,063,经皮东京株n=760,632),确定性链接国家免疫、结核监测和医保登记数据,随访至结局或2023年12月31日。

主要发现

  • 淋巴腺炎在皮内丹麦株组发生42,385/457,063例(9.27%),经皮东京株组发生67,466/760,632例(8.87%)(P<0.001),校正风险比aHR=1.00(95%CI 0.99-1.02)。
  • 骨炎在皮内丹麦株组142例、经皮东京株组209例(各约0.03%),aHR=1.01(95%CI 0.80-1.26)。

临床怎么用

  • 作者认为两种接种方法均安全有效,选择可依据疫苗供应、接种后勤和地方偏好,而非预期结局差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whether differences in BCG strain and administration (intradermal Danish-1331 vs transcutaneous Tokyo-172) translate into meaningful variation in safety remains uncertain. South Korea's dual BCG policy enables a head-to-head comparison. METHODS: We conducted a nationwide retrospective cohort of all children born 2014-2018 who received BCG in infancy (N = 1,217,695; Danish/intradermal n = 457,063; Tokyo/transcutaneous n = 760,632). National immunization, tuberculosis surveillance, claims registries were deterministically linked. Children were followed from vaccination until outcome or 31 December 2023. Incidence rates (IRs) were calculated, and Cox models adjusted for birth year, sex, socio-economic status, and region estimated adjusted hazard ratios (aHRs). RESULTS: The study cohort comprised 1,217,690 infants born between 2014 and 2018 who received BCG vaccination in infancy. Of these, 457,063 (37.5 %) received intradermal BCG (Danish 1331 strain) and 760,632 (62.5 %) received transcutaneous BCG (Tokyo 172 strain). Lymphadenitis occurred more often after intradermal BCG (42,385/457,063; 9.27 %) than after transcutaneous BCG (67,466/760,632; 8.87 %) (p < 0.001), with an adjusted hazard ratio of 1.00 (95 % CI, 0.99-1.02). Osteitis was rare in both groups (142 vs. 209 cases; ∼0.03 % each; aHR = 1.01; 95 % CI, 0.80-1.26). CONCLUSIONS: In this large real-world cohort, intradermal BCG (Danish-1331) and transcutaneous BCG (Tokyo-172) provided equivalent protection against pediatric tuberculosis. Intradermal vaccination was associated with only a very small increase in lymphadenitis, while serious adverse events were uncommon with both methods. These findings support programmatic flexibility in BCG vaccination policy: both methods are safe and effective, so selection can be guided by vaccine supply, delivery logistics, and local preferences rather than expected differences in outcomes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lee YH, Gwak E, Kang HM, et al. Safety of intradermal Danish- vs. transcutaneous Tokyo-strain BCG vaccination in Korean children: A nationwide cohort study. Vaccine. 2025. PMID: 41045632. doi:10.1016/j.vaccine.2025.127828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。